SMLR News and Press, Semler Scientific Inc From 02/28/22

Semler Scientific press release (NASDAQ:SMLR): Q4 Non-GAAP EPS of $0.33 misses by $0.08. Revenue of $11.5M (-5.0% Y/Y) misses by $1.55M. Shares -11%. Semler Scientific will host a conference call on Monday at 4:30 p.m. ET. to address results as well as provide a business update on its ma...

Semler Reports Fourth Quarter and Year-to-Date 2021 Financial Results 2021 HIGHLIGHTS compared to 2020: -- Annual revenues increased by 37% -- Net income increased by 23% -- Cash at December 31, 2021 increased to $37.3 million from $22.1 million PR Newswire ...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

Semler operates in a niche market in which it has the only viable alternative to standard tests for peripheral arterial disease. The company has shifted the cost of evangelizing its product, QuantFlo, to its customers, allowing it to grow quickly and profitably. The company’...

Semler to Report Fourth Quarter and Year End 2021 Financial Results and Host Conference Call on February 28, 2022 PR Newswire SANTA CLARA, Calif. , Feb. 17, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solut...

Shares of Semler Scientific (NASDAQ: SMLR) -- a medical device software company providing innovative software for peripheral artery disease (PAD) testing -- fell 25% after the company disappointed investors in its third-quarter earnings. For those unfamiliar, Semler Scientific i...

A legal victory took center stage in Tuesday's midday trading, sparking massive rallies in Teva Pharmaceutical Industries (NYSE:TEVA) and Endo International (NASDAQ:ENDP). A judge took the companies' side in a $50B case related to the opioid crisis. Fabrinet (NYSE:FN) was another major gainer...

Gainers: Kiniksa Pharmaceuticals (NASDAQ:KNSA) +13%, Ocugen (NASDAQ:OCGN) +13%, Calliditas Therapeutics (NASDAQ:CALT) +11%, Context Therapeutics (NASDAQ:CNTX) +10%, Bone Biologics (OTCPK:BBLG) +7%. Losers: ABVC BioPharma (NASDAQ:ABVC) -32%, Semler ...

Semler Scientific (NASDAQ:SMLR) has crashed ~22.9% in the pre-market after the company's Q3 2021 financials fell short of expectations. The Revenue missed the consensus by as much as ~1.1M for the first time in 10 quarters, as shown in the graph below. While revenue r...

Semler Scientific, Inc. (SMLR) Q3 2021 Earnings Conference Call November 01, 2021, 04:30 PM ET Company Participants Doug Murphy-Chutorian - CEO Dennis Rosenberg - Chief Marketing Officer Andy Weinstein - SVP, Finance and Accounting Conference Call Participants Kyle Bauser - Colliers Securitie...